Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease

IF 0.3 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
N. A. Shatalova, D. Sychev, K. Mirzaev, A. I. Kochetkov, E. Y. Ebzeeva, V. B. Dashabylova, P. Bochkov, S. N. Tuchkova, S. V. Glagolev
{"title":"Pharmacogenetics and pharmacokinetics of rivaroxaban in patients with atrial fibrillation and chronic kidney disease","authors":"N. A. Shatalova, D. Sychev, K. Mirzaev, A. I. Kochetkov, E. Y. Ebzeeva, V. B. Dashabylova, P. Bochkov, S. N. Tuchkova, S. V. Glagolev","doi":"10.20996/1819-6446-2023-2970","DOIUrl":null,"url":null,"abstract":"Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF) and stage 3 and 4 chronic kidney disease (CKD).Material and methods. A total of 123 patients 52 to 97 years old (median age, 82 years) with AF in combination with stage 3 and 4 CKD were included in the study. Each patient underwent a pharmacogenetic and pharmacokinetic study.Results. Cmin,ss and dose-adjusted concentration (Cmin,ss/D) of rivaroxaban were significantly higher in patients with the TT genotype than with the CT genotype of the polymorphic variant rs1045642 of the ABCB1 gene (Сmin,ss 60,5 [36,7;173] ng/ml and 54,8 [23,1;97,3] ng/ml, respectively, р=0,016; Сmin,ss/D 4,06[2,3;8,1] ng/ml/mg and 2,2 [1,1;4,9] ng/ml/mg, р=0,006). In patients with the T allele (CT and TT genotypes), compared with CC genotype carriers, Cmin,ss and Cmin,ss/D were significantly higher (Cmin,ss 60,5 [36,7;173] ng/ml and 45,8 [20,9;82,3] ng/ml, respectively, p=0,029; Cmin,ss/D 4,06 [2,3;8,1] ng/ml/  mg and 2,6 [1,2;4,8] ng/ml/mg, respectively, p=0,014). Also, Cmin,ss and Cmin,ss/D was significantly higher in patients with the TT genotype according to the polymorphic variant rs2032582 of the ABCB1 gene than in patients with the GG genotype (p=0,02 and р=0,016 respectively). Cmin,ss and Cmin,ss/D in T allele (GT and TT genotypes) carriers were significantly higher than in T allele homozygotes (Cmin,ss 57,1 [27,7;106,0] ng/ml versus 37,6 [18,6;61,7] ng/ml respectively, p=0,024; Cmin,ss/D 3,6 [1,7;7,4] ng/ml/mg versus 2,3 [1,1;4,09] ng/ml/mg respectively, p=0,032). Differences in Сmin,ss and Сmin,ss/D of rivaroxaban were detected when comparing TC, CC and TT genotypes of polymorphism rs1128503 of the ABCB1 gene. When comparing Сmin,ss and Сmin,ss/D of rivaroxaban among carriers of AG and GG genotypes of the rs776746 polymorphism of the CYP3A56986A>G gene, no significance was detected (p>0,05). Also, no difference in Cmin,ss and Cmin,ss/D was found when comparing carriers of the CC and CT genotypes of the rs35599367 polymorphism of the CYP3A4 gene, and carriers of the CC and AC genotypes of the rs890293 polymorphism of the CYP2J2 gene (p>0,05).Conclusion. The carriage of T allele by polymorphic variants rs1045642 and rs2032582 of the ABCB1 gene affects Cmin,ss and Cmin,ss/D of rivaroxaban.","PeriodicalId":20812,"journal":{"name":"Rational Pharmacotherapy in Cardiology","volume":"6 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rational Pharmacotherapy in Cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20996/1819-6446-2023-2970","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Aim. To study the possible relationship between polymorphic variants of ABCB1 (rs2032582, rs1045642, rs1128503), CYP3A5 (rs776746), CYP3A4 (rs35599367) and CYP2J2 (rs890293) genes with residual equilibrium concentrations (Cmin,ss) of rivaroxaban in patients with non-valvular atrial fibrillation (AF) and stage 3 and 4 chronic kidney disease (CKD).Material and methods. A total of 123 patients 52 to 97 years old (median age, 82 years) with AF in combination with stage 3 and 4 CKD were included in the study. Each patient underwent a pharmacogenetic and pharmacokinetic study.Results. Cmin,ss and dose-adjusted concentration (Cmin,ss/D) of rivaroxaban were significantly higher in patients with the TT genotype than with the CT genotype of the polymorphic variant rs1045642 of the ABCB1 gene (Сmin,ss 60,5 [36,7;173] ng/ml and 54,8 [23,1;97,3] ng/ml, respectively, р=0,016; Сmin,ss/D 4,06[2,3;8,1] ng/ml/mg and 2,2 [1,1;4,9] ng/ml/mg, р=0,006). In patients with the T allele (CT and TT genotypes), compared with CC genotype carriers, Cmin,ss and Cmin,ss/D were significantly higher (Cmin,ss 60,5 [36,7;173] ng/ml and 45,8 [20,9;82,3] ng/ml, respectively, p=0,029; Cmin,ss/D 4,06 [2,3;8,1] ng/ml/  mg and 2,6 [1,2;4,8] ng/ml/mg, respectively, p=0,014). Also, Cmin,ss and Cmin,ss/D was significantly higher in patients with the TT genotype according to the polymorphic variant rs2032582 of the ABCB1 gene than in patients with the GG genotype (p=0,02 and р=0,016 respectively). Cmin,ss and Cmin,ss/D in T allele (GT and TT genotypes) carriers were significantly higher than in T allele homozygotes (Cmin,ss 57,1 [27,7;106,0] ng/ml versus 37,6 [18,6;61,7] ng/ml respectively, p=0,024; Cmin,ss/D 3,6 [1,7;7,4] ng/ml/mg versus 2,3 [1,1;4,09] ng/ml/mg respectively, p=0,032). Differences in Сmin,ss and Сmin,ss/D of rivaroxaban were detected when comparing TC, CC and TT genotypes of polymorphism rs1128503 of the ABCB1 gene. When comparing Сmin,ss and Сmin,ss/D of rivaroxaban among carriers of AG and GG genotypes of the rs776746 polymorphism of the CYP3A56986A>G gene, no significance was detected (p>0,05). Also, no difference in Cmin,ss and Cmin,ss/D was found when comparing carriers of the CC and CT genotypes of the rs35599367 polymorphism of the CYP3A4 gene, and carriers of the CC and AC genotypes of the rs890293 polymorphism of the CYP2J2 gene (p>0,05).Conclusion. The carriage of T allele by polymorphic variants rs1045642 and rs2032582 of the ABCB1 gene affects Cmin,ss and Cmin,ss/D of rivaroxaban.
心房颤动和慢性肾病患者利伐沙班的药物遗传学和药代动力学
目的研究 ABCB1(rs2032582、rs1045642、rs1128503)、CYP3A5(rs776746)、CYP3A4(rs35599367)和 CYP2J2(rs890293)基因的多态变异与剩余平衡浓度(Cmin,ss)之间可能存在的关系、CYP3A4(rs35599367)和 CYP2J2(rs890293)基因变异与非瓣膜性心房颤动(房颤)和 3、4 期慢性肾脏病(CKD)患者体内利伐沙班的残余平衡浓度(Cmin,ss)的关系。材料与方法研究共纳入了 123 名 52 至 97 岁(中位年龄 82 岁)的房颤合并 3 期和 4 期慢性肾脏病患者。每位患者都接受了药物遗传学和药物动力学研究。ABCB1基因多态变异体rs1045642的TT基因型患者利伐沙班的Cmin,ss和剂量调整浓度(Cmin,ss/D)明显高于CT基因型患者(Сmin,ss 60,5 [36,7;173]纳克/毫升和54,8[23,1;97,3]纳克/毫升,р=0,016;Сmin,ss/D分别为4,06[2,3;8,1]纳克/毫升/毫克和2,2[1,1;4,9]纳克/毫升/毫克,р=0,006)。在 T 等位基因(CT 和 TT 基因型)患者中,与 CC 基因型携带者相比,Cmin,ss 和 Cmin,ss/D 明显更高(Cmin,ss 60,5 [36,7;173] 纳克/毫升和 45,8 [20,9;82,3] 纳克/毫升,p=0,029;Cmin,ss/D 分别为 4,06 [2,3;8,1] 纳克/毫升/毫克和 2,6 [1,2;4,8] 纳克/毫升/毫克,p=0,014)。此外,根据 ABCB1 基因的多态变异 rs2032582,TT 基因型患者的 Cmin,ss 和 Cmin,ss/D 明显高于 GG 基因型患者(分别为 p=0,02 和 р=0,016)。T等位基因(GT和TT基因型)携带者的Cmin,ss和Cmin,ss/D明显高于T等位基因同卵双生者(Cmin,ss 57,1 [27,7;106,0] 纳克/毫升对 37,6 [18,6;61,7] 纳克/毫升,P=0,024;Cmin,ss/D 分别为 3,6 [1,7;7,4] 纳克/毫升/毫克对 2,3 [1,1;4,09] 纳克/毫升/毫克,P=0,032)。在比较 ABCB1 基因多态性 rs1128503 的 TC、CC 和 TT 基因型时,发现利伐沙班的Сmin,ss 和Сmin,ss/D 有差异。比较 CYP3A56986A>G 基因多态性 rs776746 的 AG 和 GG 基因型携带者服用利伐沙班的Сmin,ss 和Сmin,ss/D,未发现显著性差异(p>0,05)。此外,比较 CYP3A4 基因 rs35599367 多态性的 CC 和 CT 基因型携带者、CYP2J2 基因 rs890293 多态性的 CC 和 AC 基因型携带者,也未发现 Cmin,ss 和 Cmin,ss/D 的差异(P>0.05)。ABCB1基因多态变异rs1045642和rs2032582的T等位基因携带者会影响利伐沙班的Cmin,ss和Cmin,ss/D。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Rational Pharmacotherapy in Cardiology
Rational Pharmacotherapy in Cardiology CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.00
自引率
50.00%
发文量
79
审稿时长
6 weeks
期刊介绍: The primary goals of the Journal are consolidation of information on scientific and practical achievements in pharmacotherapy and prevention of cardiovascular diseases and continuing education of cardiologists and internists. The scientific concept of the edition suggests the publication of information on current achievements in cardiology, the results of national and international clinical trials. The Journal publishes original articles on the results of clinical trials designed to study the effectiveness and safety of drugs, analysis of clinical practice and its compliance with national and international recommendations, expert s’ opinions on a wide range of cardiology issues, associated conditions and clinical pharmacology. There is a heading “Preventive cardiology and public health” in the Journal to stimulate research interest in this highly demanded area. Memories of the outstanding people in medicine including cardiology, which are of great interest to historians of medicine, are published in "Our Mentors” heading.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信